Sandoz Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$7.4M
Doctors Paid
9,961
Transactions
28,056
2024 Total
$190,571
Payment Breakdown by Category
Research$5.8M (78.2%)
Consulting$837,376 (11.3%)
Food & Beverage$503,444 (6.8%)
Travel$54,255 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.8M | 279 | 78.2% |
| Consulting Fee | $837,376 | 279 | 11.3% |
| Food and Beverage | $503,444 | 25,444 | 6.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $164,138 | 70 | 2.2% |
| Travel and Lodging | $54,255 | 199 | 0.7% |
| Grant | $30,510 | 24 | 0.4% |
| Education | $27,070 | 1,759 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $2,500 | 2 | 0.0% |
Payments by Type
Research
$5.8M
279 transactions
General
$1.6M
27,777 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING TAZAROTENE CREAM 0.1% TO TAZORAC? (TAZAROTENE) CREAM 0.1% AND BOTH ACTIVE TREATMENTS TO A VEHICLE CONTROL IN THE TREATMENT OF ACNE VULGARIS | $1.9M | 0 | 25 |
| A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING TAZAROTENE CREAM 0.05% TO TAZORAC? (TAZAROTENE) CREAM 0.05% AND BOTH ACTIVE TREATMENTS TO A VEHICLE CONTROL IN THE TREATMENT OF STABLE PLAQUE PSORIASIS | $1.4M | 0 | 27 |
| PROSPECTIVE STUDY COMPARING BRAND AND GENERIC IMMUNOSUPPRESSION ON TRANSPLANT OUTCOMES, ADHERENCE, AND IMMUNE RESPONSE | $786,000 | 0 | 3 |
| PROSPECTIVE STUDY COMPARING BRAND AND GENERIC IMMUNOSUPPRESSION ON TRANSPLANT OUTCOMES, ADHERENCE, & IMMUNE RESPONSE | $376,620 | 0 | 2 |
| OPEN LABEL STUDY OF THE SOLIS DRY POWDER INHALER CONTAINING FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE WHEN USED IN NORMAL CLINICAL PRACTICE WITH PATIENTS | $191,561 | 0 | 10 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PHASE III STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY & IMMUNOGENICITY OF GP2015 AND ENBREL? (EU AUTHORIZED) IN PATIENTS WITH MODERATE TO SEVERE, ACTIVE RHEUMATOID ARTHRITIS | $187,806 | 1 | 66 |
| BIOEQUIVALENCE STUDY OF CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE TOPICAL SUSPENSION, 0.005%/0.064% | $104,060 | 0 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE PK, PD, SAFETY AND EFFICACY OF GP2013 AND RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY OR INTOLERANT TO STANDARD DMARDS AND UP TO THREE ANTI-TNF THERAPIES | $96,368 | 0 | 8 |
| A RANDOMIZED, DOUBLE- BLIND, CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF TRANSITIONING TO GP2013 OR RE-TREATMENT WITH RITUXAN? OR MABTHERA? IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PREVIOUSLY TREATED WITH RITUXAN? OR MABTHERA? | $86,079 | 0 | 55 |
| A RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE SENSITIZING POTENTIAL OF AMLACTIN ULTRA SMOOTHING / AMLACTIN FOOT REPAIR (CREAM WITH 15% LACTIC ACID), AMLACTIN RAPID RELIEF (LOTION WITH 15% LACTIC ACID) AND AMLACTIN DAILY (LOTION WITH 12% LACTIC ACID) IN HEALTHY VOLUNTEERS USING A REPEAT INSULT PATCH TEST DESIGN | $85,250 | 0 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY AND IMMUNOGENICITY OF A BIOSIMILAR ADALIMUMAB (GP2017) AND HUMIRA? IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS | $71,274 | 8 | 9 |
| A 21-DAY, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE IRRITATION POTENTIAL OF AMLACTIN ULTRA SMOOTHING INTENSELY HYDRATING CREAM / AMLACTIN FOOT REPAIR FOOT CREAM THERAPY, AMLACTIN RAPID RELIEF RESTORING LOTION + CERAMIDES, AND AMLACTIN DAILY MOISTURIZING BODY LOTION IN HEALTHY VOLUNTEERS USING A CUMULATIVE IRRITANT PATCH TEST DESIGN. | $56,625 | 0 | 2 |
| A 21-DAY, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE IRRITATION POTENTIAL OF AMLACTIN ULTRA SMOOTHING / AMLACTIN FOOT REPAIR (CREAM WITH 15% LACTIC ACID), AMLACTIN RAPID RELIEF (LOTION WITH 15% LACTIC ACID) AND AMLACTIN DAILY (LOTION WITH 12% LACTIC ACID) IN HEALTHY VOLUNTEERS USING A CUMULATIVE IRRITANT PATCH TEST DESIGN | $56,625 | 0 | 1 |
| POST-APPROVAL SAFETY STUDY TO MONITOR THE LONG-TERM SAFETY AND EFFICACY OF OMNITROPE? IN INFANTS, CHILDREN AND ADOLESCENTS (?PATRO CHILDREN? OR THE ?STUDY?) | $42,253 | 1 | 10 |
| POST-APPROVAL SAFETY STUDY TO MONITOR THE LONG-TERM SAFETY AND EFFICACY OF OMNITROPE IN INFANTS CHILDREN AND ADOLESCENTS PATRO CHILDREN OR THE STUDY | $39,500 | 1 | 9 |
| A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING TAZAROTENE CREAM 0.05% TO TAZORAC (TAZAROTENE) CREAM 0.05% AND BOTH ACTIVE TREATMENTS TO A VEHICLE CONTROL IN THE TREATMENT OF STABLE PLAQUE PSORIASIS | $29,000 | 0 | 1 |
| A RANDOMIZED DOUBLE-BLIND PARALLEL-GROUP PHASE III STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY & IMMUNOGENICITY OF GP2015 AND ENBREL? (EU AUTHORIZED) IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS | $28,999 | 1 | 12 |
| YALE NEW HAVEN HEOR STUDY | $25,810 | 0 | 1 |
| Post-Approval Safety Study to monitor the long-term safety and efficacy of Omnitrope in infants, children and adolescents | $22,600 | 0 | 7 |
| A RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE SENSITIZING POTENTIAL OF AMLACTIN ULTRA SMOOTHING / AMLACTIN FOOT REPAIR (CREAM WITH 12% LACTIC ACID) AND AMLACTIN RAPID RELIEF (LOTION WITH 12% LACTIC ACID) IN HEALTHY VOLUNTEERS USING A REPEAT INSULT PATCH TEST DESIGN | $21,313 | 0 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PHASE III STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY AND IMMUNOGENICITY OF GP2015 AND ENBREL (EU AUTHORIZED) IN PATIENTS WITH MODERATE TO SEVERE, ACTIVE RHEUMATOID ARTHRITIS | $16,757 | 0 | 4 |
| G-CSF UTILIZATION AND CLINICAL OUTCOMES AND HEALTH CARE RESOURCE UTILIZATION ASSOCIATED WITH G-CSF TREATMENT IN PATIENTS WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN A COMMUNITY ONCOLOGY SETTING | $16,000 | 1 | 1 |
| A 21-DAY, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE IRRITATION POTENTIAL OF AMLACTIN ULTRA SMOOTHING / AMLACTIN FOOT REPAIR (CREAM WITH 12% LACTIC ACID) AND AMLACTIN RAPID RELIEF (LOTION WITH 12% LACTIC ACID) IN HEALTHY VOLUNTEERS USING A CUMULATIVE IRRITANT PATCH TEST DESIGN | $14,156 | 0 | 1 |
| PATCH 2&3:PREVENTION & TREATMENT OF COVID-19 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2) WITH HYDROXYCHLOROQUINE | $11,880 | 0 | 1 |
| A RANDOMIZED, DOUBLE- BLIND, CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF TRANSITIONING TO GP2013 OR RE-TREATMENT WITH RITUXAN OR MABTHERA IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS, PREVIOUSLY TREATED WITH RITUXAN OR MABTHERA | $9,139 | 0 | 3 |
| THE PATCH TRIAL (PREVENTION AND TREATMENT OF COVID-19 WITH HYDROXYCHLOROQUINE) (PATCH) | $9,000 | 0 | 1 |
| Post Approval Safety Study to monitor the long term safety and efficacy of Omnitrope in infants children and adolescents PATRO Children or the Study | $8,800 | 1 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY AND IMMUNOGENICITY OF A BIOSIMILAR HYRIMOZ (GP2017) AND HUMIRA? IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS | $8,700 | 0 | 3 |
| POST-APPROVAL SAFETY STUDY TO MONITOR THE LONG-TERM SAFETY AND EFFICACY OF OMNITROPE IN INFANTS, CHILDREN AND ADOLESCENTS PATRO CHILDREN OR THE STUDY | $6,000 | 1 | 4 |
| CDRB436AUS37T | $4,536 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Kenneth Freedman, M.d, M.D | Internal Medicine | Jamaica Plain, MA | $13,163 | $0 |
| Charles Schiffer, Md, MD | Internal Medicine | Detroit, MI | $13,077 | $0 |
| Lee Schwartzberg, Md, MD | Hematology | Reno, NV | $13,012 | $0 |
| Dr. Nicole Kuderer, M.d, M.D | Hematology & Oncology | Seattle, WA | $12,994 | $0 |
| Dr. Daniel Kantor, M.d, M.D | Neurology | Coconut Creek, FL | $12,741 | $0 |
| Sabine Hazan, Md, MD | Gastroenterology | Ventura, CA | $12,147 | $0 |
| Silvana Martino, D.o, D.O | Hematology & Oncology | Santa Monica, CA | $12,009 | $0 |
| Dhiman Basu, Md, MD | Internal Medicine | Colleyville, TX | $10,889 | $0 |
| Jeffrey Curtis, Md, MD | Rheumatology | Birmingham, AL | $10,848 | $0 |
| Mikkael Sekeres, Md, MD | Hematology & Oncology | Miami, FL | $10,631 | $0 |
| Adda Grimberg, M.d, M.D | Pediatrics | Philadelphia, PA | $10,425 | $0 |
| Dr. Laurie Cohen, Md, MD | Pediatric Endocrinology | Bronx, NY | $10,425 | $0 |
| Gail Roboz, Md, MD | Internal Medicine | New York, NY | $10,404 | $0 |
| Ben Jacobs, Md, MD | Urology | Brooklyn, NY | $10,380 | $0 |
| Michael Frost, M.d, M.D | Internal Medicine | Ambler, PA | $10,303 | $0 |
| Russell Cohen | Gastroenterology | Chicago, IL | $10,140 | $0 |
| Jeffrey Crawford, M.d, M.D | Hematology & Oncology | Durham, NC | $9,900 | $0 |
| Dr. Radhakrishnan Ramchandren, Md, MD | Independent Medical Examiner | West Reading, PA | $9,541 | $0 |
| Kent Reifschneider, M.d, M.D | Pediatric Endocrinology | Norfolk, VA | $9,058 | $0 |
| Kami Maddocks, Md, MD | Hematology | Columbus, OH | $8,930 | $0 |
| Dr. Amanda Cashen, Md, MD | Medical Oncology | Saint Louis, MO | $8,741 | $0 |
| Randall Urban, Md, MD | Endocrinology, Diabetes & Metabolism | Galveston, TX | $8,736 | $0 |
| Nashat Gabrail, M.d, M.D | Specialist | Canton, OH | $8,473 | $0 |
| Dr. Brian Hill, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | Cleveland, OH | $8,337 | $0 |
| Heidi Crayton, Md, MD | Neurology | Vienna, VA | $8,182 | $0 |
Ad
Top Products
- TAZAROTENE $3.4M
- TACROLIMUS $1.2M
Associated Products (18)
- TAZAROTENE $3.4M
- TACROLIMUS $2.1M
- KERYDIN $447,972
- ERELZI $248,093
- SALMETEROL XINAFOATE/FLUTICA $229,400
- RITUXIMAB $196,302
- HYRIMOZ $191,174
- OMNITROPE $186,707
- ADALIMUMAB $73,041
- ZARXIO $62,452
- HYDROXYCHLOROQUINE SULFATE $31,256
- RESET-O $29,458
- TREPROSTINIL $25,855
- SALMETEROL XINAFOATE/FLUTICASONE PROPIONATE $21,925
- APEXICON E $13,929
- METHADONE $13,356
- RESET $10,671
- GLATOPA $10,236
Payment Categories
- Food & Beverage $503,444
- Consulting $837,376
- Travel & Lodging $54,255
- Research $5.8M
About Sandoz Inc.
Sandoz Inc. has made $7.4M in payments to 9,961 healthcare providers, recorded across 28,056 transactions in the CMS Open Payments database. In 2024, the company paid $190,571. The top product by payment volume is TAZAROTENE ($3.4M).
Payments were distributed across 164 medical specialties. The top specialty by payment amount is Rheumatology ($246,889 to 914 doctors).
Payment categories include: Food & Beverage ($503,444), Consulting ($837,376), Research ($5.8M), Travel & Lodging ($54,255).
Sandoz Inc. is associated with 18 products in the CMS Open Payments database, including TAZAROTENE, TACROLIMUS, and KERYDIN.